Driehaus Capital Management LLC Y M Abs Therapeutics, Inc. Transaction History

Driehaus Capital Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$13.96 - $19.67 $4.15 Million - $5.85 Million	297,252 New	297,252 $4.29 Million
Q2 2021 Aug 16, 2021	SELL	$25.45 - $37.64 $8.98 Million - $13.3 Million	-352,717 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$29.16 - $51.96 $1.98 Million - $3.53 Million	67,849 Added 23.82%	352,717 $10.7 Million
Q4 2020 Feb 16, 2021	SELL	$37.86 - $54.26 $505,241 - $724,099	-13,345 Reduced 4.47%	284,868 $14.1 Million
Q3 2020 Nov 16, 2020	SELL	$35.13 - $43.62 $1.25 Million - $1.55 Million	-35,647 Reduced 10.68%	298,213 $11.4 Million
Q2 2020 Aug 14, 2020	SELL	$23.66 - $49.53 $2.62 Million - $5.48 Million	-110,576 Reduced 24.88%	333,860 $14.4 Million
Q1 2020 May 15, 2020	SELL	$14.39 - $35.8 $40,378 - $100,454	-2,806 Reduced 0.63%	444,436 $11.6 Million
Q4 2019 Feb 12, 2020	BUY	$23.81 - $33.78 $5.72 Million - $8.11 Million	240,153 Added 115.97%	447,242 $14 Million
Q3 2019 Nov 14, 2019	BUY	$21.57 - $31.37 $156,296 - $227,307	7,246 Added 3.63%	207,089 $5.4 Million
Q2 2019 Aug 14, 2019	BUY	$19.51 - $28.31 $3.9 Million - $5.66 Million	199,843 New	199,843 $4.57 Million

106

24.5M

40.3K

400

Ticker YMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,719,500
Market Cap $487M
Description
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...

Get notified when there are updates to the investment portfolio of Driehaus Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Driehaus Capital Management LLC with notifications on news.